About Fortrea Clinical Development Private Limited
Data last updated:
Fortrea Clinical Development Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Chiltern International Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 24 September 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U73100KA2002PTC031038. Its GSTIN is 29AAACO5605N1Z4 (Karnataka). The company holds 4 GST registrations, all of them active.
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹2.42 Lakh. It was formerly known as Omnicare Clinical Research India Private Limited and Covance Clinical Development Private Limited. It is led by directors David Howard Cooper and Rishi Raj Sharma.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bangalore, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹64.26 Cr, a decline of 8% compared to the previous year. For the same year it recorded a net profit of ₹8.66 Cr (net margin 13.5%) and EBITDA of ₹13.98 Cr (EBITDA margin 21.7%). Revenue has declined at a compounded annual rate (CAGR) of 13% over three years and 10% over five years.
The company has about 219 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Covance. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹17.56 Cr; the latest was in September 2018. Its 10 peer companies in the Pharma industry (Contract Research) are compared by revenue, 5 larger and 5 smaller; the largest is Sun Pharma Advanced Research Company Limited with revenue of ₹73.56 Cr. The company has 8 MSME Form 1 returns on record between 2019 and 2023, listing 13 overdue payments to 8 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website drugdevelopment.labcorp.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressSattva Knowledge Court 2nd Floor Wing B Plot No. 9 Katha No. 299 Sy. No. 77, Doddenakkundi Phase I Industrial Area Whitefield Road, Bangalore, Karnataka, India – 560048
- IndustryPharma, Pharma Contract R&D
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Fortrea Clinical Development Private Limited
The main business activity of Fortrea Clinical Development is professional, scientific and technical. In detail, this covers scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Fortrea Clinical Development Private Limited FY 2025 filings available
Fortrea Clinical Development Private Limited reported revenue of ₹64.26 Cr (down 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Fortrea Clinical Development Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 10% over five years, including a 8% fall in the latest year. EBITDA rose 45% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Fortrea Clinical Development Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹13.98 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹8.66 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Fortrea Clinical Development Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 21.7% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 13.5% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Fortrea Clinical Development are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Fortrea Clinical Development Private Limited
Fortrea Clinical Development Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Contract Research). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sun Pharma Advanced Research Company Limited Listed | ₹73.56 Cr (FY 2025) | •••• | •••• | -30.0% | •••• | Manjusar, Gujarat, India |
| Actavis Pharma Development Centre Private Limited | ₹70.35 Cr (FY 2025) | •••• | •••• | -4.0% | •••• | Mumbai, Maharashtra, India |
| Uthishtaa Solutions Private Limited | ₹69.13 Cr (FY 2024) | •••• | •••• | -53.0% | •••• | Hyderabad, Telangana, India |
| RCC Laboratories India Private Limited | ₹68.9 Cr (FY 2025) | •••• | •••• | 31.0% | •••• | Telangana, India |
| Axxelent Pharma Science Private Limited | ₹64.29 Cr (FY 2025) | •••• | •••• | 237.0% | •••• | Chennai, Tamil Nadu, India |
| Fortrea Clinical Development Private Limited this company | ₹64.26 Cr (FY 2025) | •••• | •••• | -8.0% | •••• | Bangalore, Karnataka, India |
| Thinq Pharma-Cro Limited | ₹62.89 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | Mumbai, Maharashtra, India |
| Lyrus Life Sciences Private Limited | ₹60.95 Cr (FY 2025) | •••• | •••• | -22.0% | •••• | Bangalore, Karnataka, India |
| Palamur Biosciences Private Limited | ₹60.63 Cr (FY 2023) | •••• | •••• | 39.0% | •••• | Secunderabad, Telangana, India |
| Diagnosearch Life Sciences Private Limited. | ₹60.46 Cr (FY 2025) | •••• | •••• | 0.0% | •••• | Thane, Maharashtra, India |
| MMSH Clinical Research Private Limited | ₹60.32 Cr (FY 2025) | •••• | •••• | 3.0% | •••• | Bangalore, Karnataka, India |
Peers are the five companies nearest above and the five nearest below Fortrea Clinical Development by revenue in the Pharma industry (Contract Research), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Fortrea Clinical Development Private Limited
Fortrea Clinical Development Private Limited is audited by Vasan & Sampath LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Vasan & Sampath LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Fortrea Clinical Development Private Limited
Fortrea Clinical Development has 2 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| David Howard Cooper | Director | 30 Jun 2023 | 3 Years 3 Months | Current |
| Rishi Raj Sharma | Director | 11 Sep 2023 | 3 Years 0 Months | Current |
Ownership and Shareholding of Fortrea Clinical Development Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Fortrea Clinical Development Private Limited
Fortrea Clinical Development Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Fortrea Clinical Development Private Limited
Fortrea Clinical Development Private Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹17.56 Cr; the latest was in September 2018.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2018 | Funding round | ₹17.56 Cr | Investors: Chiltern International Limited |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: Theorem Clinical Research International Bv, Theorem Clinical Research Holdings Bv Seller: Omnicare Clinical Research International B.V.,, Omnicare Clinical Research Holdings B.V., |
Full deal history
All 2 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
MSME Payment Delays by Fortrea Clinical Development Private Limited
Fortrea Clinical Development Private Limited has 8 MSME Form 1 returns on record between 2019 and 2023, listing 13 overdue payments to 8 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 8)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| Rentokil Initial Hygiene India Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Janani Tours and Resorts Private Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 8 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Fortrea Clinical Development Private Limited
Fortrea Clinical Development operates one associated brand: Covance. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| CRO offering comprehensive drug development solutions from drug discovery to life cycle management | covance.com |
Employees and EPFO Compliance at Fortrea Clinical Development Private Limited
Fortrea Clinical Development Private Limited has a workforce of 219 employees as of Mar 24, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Name History of Fortrea Clinical Development Private Limited
Fortrea Clinical Development has undergone 5 name changes throughout its history. The current legal name is Fortrea Clinical Development Private Limited.
| Company Name | Status |
|---|---|
| Fortrea Clinical Development Private Limited | Current |
| Omnicare Clinical Research India Private Limited | Previous |
| Covance Clinical Development Private Limited | Previous |
| Labcorp Clinical Development Private Limited | Previous |
| Theorem Clinical Research India Private Limited | Previous |
| Chiltern Clinical Research India Private Limited | Previous |
Recent Activity on Fortrea Clinical Development Private Limited
Fortrea Clinical Development Private Limited has 21 board changes on record since 2006: 3 appointments and 18 cessations. The latest: David Howard Cooper ceased to be Additional Director on 25 Sep 2023.
12 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Fortrea Clinical Development Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Fortrea Clinical Development Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Fortrea Clinical Development Private Limited
Fortrea Clinical Development has 4 GST registrations: 4 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAACO5605N1Z4 | Karnataka | Active | 01 Jul 2017 |
| 29AAACO5605N2Z3 | Karnataka | Active | 27 Mar 2025 |
| 27AAACO5605N1Z8 | Maharashtra | Active | 26 Jul 2017 |
| 33AAACO5605N1ZF | Tamil Nadu | Active | 26 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Fortrea Clinical Development Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fortrea Clinical Development Private Limited
Fortrea Clinical Development is an active private limited company based in Bangalore, Karnataka, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 24 September 2002 (24+ years old) and is registered under CIN U73100KA2002PTC031038.
Fortrea Clinical Development reported revenue of ₹64.26 Cr for FY 2025 (down 8% YoY).
Fortrea Clinical Development has 2 current directors:
- David Howard Cooper - Director
- Rishi Raj Sharma - Director
Fortrea Clinical Development reported a net profit of ₹8.66 Cr (net margin 13.5%) and EBITDA of ₹13.98 Cr (EBITDA margin 21.7%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Fortrea Clinical Development is -13% over three years and -10% over five years. In the latest year (FY 2025) revenue fell 8%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Fortrea Clinical Development is 29AAACO5605N1Z4, registered in Karnataka. The company has 4 GST registrations in all, of which 4 are active. Other active GSTINs include 29AAACO5605N2Z3 (Karnataka), 27AAACO5605N1Z8 (Maharashtra), 33AAACO5605N1ZF (Tamil Nadu).
The CIN (Corporate Identification Number) of Fortrea Clinical Development is U73100KA2002PTC031038. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Fortrea Clinical Development was incorporated on 24 September 2002, making it 24+ years old. It is registered with the Registrar of Companies, Bangalore.
Fortrea Clinical Development has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹17.56 Cr; the latest was in September 2018.
The peers of Fortrea Clinical Development by revenue are Sun Pharma Advanced Research Company Limited, Actavis Pharma Development Centre Private Limited, Uthishtaa Solutions Private Limited, RCC Laboratories India Private Limited, Axxelent Pharma Science Private Limited and 5 more, all in the Pharma industry (Contract Research).
David Howard Cooper ceased to be Additional Director on 25 Sep 2023. Rishi Raj Sharma ceased to be Additional Director on 25 Sep 2023. Rishi Raj Sharma was appointed as Director on 11 Sep 2023. Fortrea Clinical Development has 21 board changes on record in total.
Fortrea Clinical Development has 8 MSME Form 1 returns on record between 2019 and 2023, listing 13 overdue payments to 8 micro and small suppliers. The latest return was filed on 17 Nov 2023.